Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q3 EPS of ($0.21), $0.03 worse than the analyst estimate of ($0.18).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.